Loading...
OTCM
NSTGQ
Market cap3mUSD
Jun 25, Last price  
0.07USD
Name

NanoString Technologies Inc

Chart & Performance

D1W1MN
OTCM:NSTGQ chart
P/E
P/S
0.03
EPS
Div Yield, %
Shrs. gr., 5y
14.35%
Rev. gr., 5y
2.06%
Revenues
127m
-12.28%
34,422,00011,730,00017,800,00022,973,00031,403,00047,593,00062,667,00086,489,000114,905,000106,732,000125,568,000117,316,000145,085,000127,262,000
Net income
-160m
L+38.43%
-44,114,000-12,768,000-10,932,000-17,708,000-29,281,000-50,038,000-45,581,000-47,089,000-43,562,000-77,400,000-40,696,000-110,078,000-115,254,000-159,543,000
CFO
-129m
L+42.03%
-10,965,000-10,692,000-14,808,000-31,346,000-38,061,000-43,362,000-6,079,000-51,657,000-54,065,000-89,421,000-81,662,000-90,549,000-128,606,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
IPO date
Jun 26, 2013
Employees
703
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT